Inhibitor Therapeutics INTI Stock
Inhibitor Therapeutics Price Chart
Inhibitor Therapeutics INTI Financial and Trading Overview
| Inhibitor Therapeutics stock price | 0.08 USD |
| Previous Close | 0.03 USD |
| Open | 0.03 USD |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.03 - 0.03 USD |
| 52 Week Range | 0.02 - 0.11 USD |
| Volume | 2.91K USD |
| Avg. Volume | 19.39K USD |
| Market Cap | 6M USD |
| Beta (5Y Monthly) | -0.49014 |
| PE Ratio (TTM) | 1.1633333 |
| EPS (TTM) | -0.02 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
INTI Valuation Measures
| Enterprise Value | -4787360 USD |
| Trailing P/E | 1.1633333 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.7755555 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Inhibitor Therapeutics Stock Price History
| Beta (5Y Monthly) | -0.49014 |
| 52-Week Change | -56.25% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.11 USD |
| 52 Week Low | 0.02 USD |
| 50-Day Moving Average | 0.04 USD |
| 200-Day Moving Average | 0.06 USD |
INTI Share Statistics
| Avg. Volume (3 month) | 19.39K USD |
| Avg. Daily Volume (10-Days) | 6.89K USD |
| Shares Outstanding | 171.79M |
| Float | 75.47M |
| Short Ratio | 0.07 |
| % Held by Insiders | 28.25% |
| % Held by Institutions | 0% |
| Shares Short | 19.88K |
| Short % of Float | 0.36% |
| Short % of Shares Outstanding | 0.22% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -13.69% |
| Return on Equity (ttm) | 585.07% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | 11.53M USD |
| Diluted EPS (ttm) | 0.03 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 10.78M USD |
| Total Cash Per Share (mrq) | 0.06 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 138.128 |
| Book Value Per Share (mrq) | 0.045 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 11.03M USD |
| Levered Free Cash Flow (ttm) | -1255798 USD |
Profile of Inhibitor Therapeutics
| Country | United States |
| State | FL |
| City | Tampa |
| Address | 900 West Platt Street |
| ZIP | 33606-2173 |
| Phone | (813) 864-2562 |
| Website | https://inhibitortx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 3 |
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.
Q&A For Inhibitor Therapeutics Stock
What is a current INTI stock price?
Inhibitor Therapeutics INTI stock price today per share is 0.08 USD.
How to purchase Inhibitor Therapeutics stock?
You can buy INTI shares on the Other OTC exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Inhibitor Therapeutics?
The stock symbol or ticker of Inhibitor Therapeutics is INTI.
Which industry does the Inhibitor Therapeutics company belong to?
The Inhibitor Therapeutics industry is Biotechnology.
How many shares does Inhibitor Therapeutics have in circulation?
The max supply of Inhibitor Therapeutics shares is 172.02M.
What is Inhibitor Therapeutics Price to Earnings Ratio (PE Ratio)?
Inhibitor Therapeutics PE Ratio is now.
What was Inhibitor Therapeutics earnings per share over the trailing 12 months (TTM)?
Inhibitor Therapeutics EPS is -0.02 USD over the trailing 12 months.
Which sector does the Inhibitor Therapeutics company belong to?
The Inhibitor Therapeutics sector is Healthcare.